Clinical Trials Logo
  1. Home
  2. Chikungunya Virus Infection
  3. NCT04838444

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Chikungunya Virus Infection Clinical Trial

Official title:
An Open-Label, Single Arm Study To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) In Adults Aged 18 Years and Above

Clinical Trial Summary

In this open-label Phase 3b, single arm study, persistence of antibodies and long term safety will be evaluated in up to 375 subjects rolled over from study VLA1553-301 (NCT number: NCT04546724).

Clinical Trial Description

In this open-label Phase 3b, single arm study, persistence of antibodies and long term safety in up to 375 subjects rolled over from study VLA1553-301 (NCT number: NCT04546724) These subjects will have annual follow-up visits at Months 12, 24, 36, 48 and 60 after immunization. The primary objective of this study will be to evaluate persistence of antibodies annually from 1 to 5 years after the single immunization with VLA1553. The secondary objective is to evaluate long-term safety 6 months to 2 years after the single immunization with VLA1553. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04838444
Study type Interventional
Source Valneva Austria GmbH
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 2, 2021
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02230163 - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Phase 1/Phase 2
Completed NCT04546724 - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Phase 3
Terminated NCT04455919 - Yoga for Chronic Chikungunya N/A
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting NCT04441905 - Phase 1 Study of SAR440894 vs Placebo Phase 1
Completed NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Phase 2
Completed NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine Phase 1
Completed NCT03807843 - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) Phase 2
Completed NCT04909411 - Consequences of a Maternal-fetal Chikungunya Virus Infection N/A
Completed NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Phase 3
Completed NCT02553369 - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection N/A
Recruiting NCT06106581 - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years Phase 2
Recruiting NCT06007183 - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination Phase 3
Completed NCT03635086 - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Phase 2
Completed NCT02861586 - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Phase 2
Completed NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase 2
Recruiting NCT06028841 - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV) Phase 3